UNION therapeutics' COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication
UNION therapeutics' COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication The Lancet Regional Health - Europe has published the results of UNION therapeutics' phase 1 study of inhaled and intranasal niclosamide products (UNI91103 and UNI91104) The study endpoints were to assess the safety profile and the pharmacokinetic profile of niclosamide when administered as a nasal spray and as an inhalation product (nebulizer) The study was placebo-controlled and conducted in healthy volunteers No adverse effects were identified, paving the way for further investigation in COVID-...
Source: prnewswire.com
